The Human Microbiome—Our Body's Secret Weapon
New research on the role of microbes in fighting disease is transforming the way medicine views bacteria, writes Lee Jones.
Crowdfunding: The Open-Source Option Against Capital Crunch
Is crowdfunding an attractive alternative to finance pharma and biotech start-ups? Seth R. Ogden and M. Andrew Holtman report.
Ebola Crisis Challenges Pharma R&D
Companies gain support-and pressure-to deliver new treatments for spreading outbreak.
Gain a Competitive Edge: Think Like a Navy SEAL
Pharmaceutical professionals, teams, and organizations can succeed at an elite level by tackling the tough mental challenges of Navy SEAL training.
Eruptions on the Drug-Pricing Horizon in Europe
An escalating political debate over pharma pricing and reimbursement nears the boiling point.
New Patent-Defense Path for Pharma
Inter Partes Review can potentially offer a more economical and streamlined litigation strategy for pharma and biotech players, writes David Dalke.
The Gate Keeper: Dr. David Haslam, Chair of NICE, UK
NICE's David Haslam discusses the UK drug watchdog's new challenge in meeting expectations around what quantitative calculations of value mean to patient access today.
Dealmaking: Staying Ahead of the Curve
Amid the continued surge in M&A activity, Michael Swanick asks, what are the crucial considerations pharma executives should weigh before sitting down at the deals table?
